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Increased TIMP-3 expression alters 
the cellular secretome through dual 
inhibition of the metalloprotease 
ADAM10 and ligand-binding of the 
LRP-1 receptor
Simone D. Scilabra1,2, Martina Pigoni1, Veronica Pravatá  1, Tobias Schätzl1, 
Stephan A. Müller1, Linda Troeberg  3 & Stefan F. Lichtenthaler1,2,4,5
The tissue inhibitor of metalloproteinases-3 (TIMP-3) is a major regulator of extracellular matrix 
turnover and protein shedding by inhibiting different classes of metalloproteinases, including 
disintegrin metalloproteinases (ADAMs). Tissue bioavailability of TIMP-3 is regulated by the endocytic 
receptor low-density-lipoprotein receptor-related protein-1 (LRP-1). TIMP-3 plays protective roles in 
disease. Thus, different approaches have been developed aiming to increase TIMP-3 bioavailability, 
yet overall effects of increased TIMP-3 in vivo have not been investigated. Herein, by using unbiased 
mass-spectrometry we demonstrate that TIMP-3-overexpression in HEK293 cells has a dual effect on 
shedding of transmembrane proteins and turnover of soluble proteins. Several membrane proteins 
showing reduced shedding are known as ADAM10 substrates, suggesting that exogenous TIMP-3 
preferentially inhibits ADAM10 in HEK293 cells. Additionally identified shed membrane proteins may 
be novel ADAM10 substrate candidates. TIMP-3-overexpression also increased extracellular levels of 
several soluble proteins, including TIMP-1, MIF and SPARC. Levels of these proteins similarly increased 
upon LRP-1 inactivation, suggesting that TIMP-3 increases soluble protein levels by competing for their 
binding to LRP-1 and their subsequent internalization. In conclusion, our study reveals that increased 
levels of TIMP-3 induce substantial modifications in the cellular secretome and that TIMP-3-based 
therapies may potentially provoke undesired, dysregulated functions of ADAM10 and LRP-1.
The tissue inhibitors of metalloproteinases (TIMPs) are a family of proteins that modulate extracellular matrix 
(ECM) turnover by regulating the proteolytic activity of matrix metalloproteinases (MMPs)1. Among the four 
mammalian TIMPs, TIMP-3 has the broadest inhibitory profile, being able to inhibit not only MMPs, but also 
members of the related families of disintegrin metalloproteinases (ADAMs) and ADAMs with thrombospondin 
motifs (ADAMTSs). TIMP-3 is a major regulator of proteolysis in vivo and its genetic ablation in mouse induces 
a number of disease-like phenotypes, including dysregulated inflammation and signs of arthritis2,3. TIMP-3 is a 
secreted, soluble protein. ECM levels of TIMP-3 are finely regulated, and this occurs at different levels: transcrip-
tionally, in response to growth factors or by promoter methylation4,5, post-transcriptionally by microRNAs6,7 
and post-translationally by endocytosis via the low-density lipoprotein receptor-related protein-1 (LRP-1)8,9, an 
endocytic receptor belonging to the LDL receptor family10.
In humans, loss of TIMP-3 is associated with several pathological conditions. Decreased levels of TIMP-3 are 
present in degraded human osteoarthritis cartilage compared to normal cartilage11. Low expression of TIMP-3 
and subsequent lack of metalloproteinase inhibition has been associated with poor prognosis in a range of human 
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cancers12,13 and with the pathogenesis of inflammatory vascular disorders14. Conversely, increased TIMP-3 levels 
have been shown to be protective in diseases characterized by enhanced proteolysis, and strategies to increase 
its bioavailability in the tissue have been widely sought as potential therapeutics. For example, intra-articular 
injection of TIMP-3 inhibited cartilage breakdown in a rat model of osteoarthritis15, and adenovirus-mediated 
gene delivery of TIMP-3 reduced invasion and survival of melanoma16. Nevertheless, overall effects of increased 
TIMP-3 on cell behavior are unknown, and it is difficult to predict whether TIMP-3-based therapies may lead to 
side effects due to sustained high levels of the inhibitor. Indeed, recent proteomic-based studies have uncovered 
a large number of novel metalloproteinase substrates and, therefore, new biological roles for these enzymes, sug-
gesting that their aberrant inhibition can lead to detrimental consequences for the tissue17.
In this study, we used shotgun proteomics and label free quantification (LFQ) in order to evaluate conse-
quences in the cell secretome induced by increased TIMP-3 expression, and identified proteins and the related 
molecular pathways that can be altered by high levels of the inhibitor. We found that TIMP-3 had a dual effect 
leading to a) inhibited shedding of several transmembrane proteins, in particular substrates of ADAM10 and b) 
increased levels of several LRP-1 ligands, likely due to a competition for their binding to the endocytic receptor.
Results
TIMP-3 overexpression inhibits shedding of several ADAM10 substrates. We used unbiased pro-
teomics to evaluate effects of increased TIMP-3 expression on cell secretion and shedding. We analysed the condi-
tioned media of TIMP-3 stably overexpressing HEK293 cells (TIMP3/HEK18) grown in the absence of serum for 
48 h. Out of all proteins detected in the conditioned media of either TIMP3-overexpressing or control HEK293 
cells, 221 were annotated as secreted proteins (based on Uniprot annotation) and 379 as membrane proteins 
(Fig. 1A). The 379 proteins annotated as membrane proteins comprise both integral and peripheral membrane 
proteins. Among them are 16 GPI-anchored proteins, 88 type 1 and 46 type 2 and 3 integral single-span mem-
brane proteins (Fig. 1B, Supplemental Table 1). Label-free quantification (LFQ) analysis confirmed that low levels 
of endogenous TIMP-3 were detected in the conditioned medium of control HEK293 cells, with a clear increase in 
the conditioned media of the TIMP-3 stably transfected cells (Fig. 1C, Table 1. As a result of the increased TIMP3 
expression, numerous additional proteins besides TIMP-3 showed altered levels in the secretome (Fig. 1C). 
Proteins were arbitrarily considered as hits when the p-value of their change was below 0.05 (measured with a 
two-sided Student t-test without correction for multiple hypothesis testing) and when their levels changed by at 
least 30%. This yielded 210 regulated proteins, of which 114 exhibited reduced levels and 96 exhibited increased 
levels, including TIMP-3. Figure 1D displays selectively the membrane proteins out of all identified proteins. 
Among the membrane proteins with reduced levels were 17 proteins annotated as type-1 and 8 annotated as 
type-2 membrane proteins, suggesting that the increased TIMP3 levels may have reduced the proteolytic release 
of their ectodomains. (Fig. 1D). To test this possibility, the ‘quantitative analysis of regulated intramembrane pro-
teolysis’ (QARIP) webserver was used, which allows mapping identified peptides to the protein transmembrane 
topology19. QARIP analysis of TIMP3/HEK secretome revealed that the identified peptides of these transmem-
brane proteins match only with their ectodomain, but not transmembrane or intracellular domains, in agreement 
with an inhibition of their metalloproteinase-mediated shedding in the presence of increased TIMP-3 (Fig. 1E). 
Seven out of the 17 type-1 membrane proteins, including amyloid precursor protein-like 2 (APLP2)20,21, amyloid 
precursor protein (APP)22–24, cell adhesion molecule 1 (CADM1)25, Ephrin-B2 (EFNB2)26, neogenin 1 (NEO1)27, 
neuropilin-1 (NRP1)28 and receptor-type tyrosine-protein phosphatase kappa (PTPRK)27, have previously been 
identified as ADAM10 substrates, indicating that TIMP3 predominantly blocks activity of ADAM10 in this cellu-
lar system. To validate the mass spectrometry LFQ results, we used immunoblotting as an orthogonal method to 
analyse the shedding of one of the reduced membrane proteins, the known ADAM10 substrate APP22,24,29. Indeed, 
levels of total soluble APP (sAPP) and sAPPα (which is specifically generated by ADAM10 cleavage22) in the con-
ditioned media were lower in the TIMP-3 expressing cells (Fig. 2A,B), indicating decreased ADAM10-dependent 
shedding of APP in agreement with the mass spectrometry data and previous reports30. As a result of the reduced 
shedding, full length APP was slightly more abundant in TIMP-3/HEK cell lysates. As a control, immunoblotting 
clearly detected TIMP-3 in the conditioned media of TIMP3/HEK cells, while it was almost undetectable in the 
conditioned media of HEK293 cells (Fig. 2A,E).
Besides known ADAM10 substrates, the ectodomains of 18 other transmembrane proteins were also found 
to be less abundant in the secretome of TIMP-3 expressing cells, including transforming growth factor beta 
receptor type 3 (TGFBR3), which has been identified as an MMP-14 substrate31, ephrin type-A receptor 4 
(EphA4) and neuropilin-2, shed by an as yet unidentified metalloproteinase32,33 (Table 1, Fig. 1D, Supplemental 
Table 1). In addition, the ectodomains of protocadherin-9 (PCDH9), prostaglandin F2 receptor negative regu-
lator (PTGFRN), proprotein convertase subtilisin/kexin type-5 (PCSK5), anthrax toxin receptor 1 (ANTXR1), 
Trans-Golgi network integral membrane protein 2 (TGOLN2) and alpha/beta hydrolase domain-containing pro-
tein 14A (ABHD14A) were less abundant in the conditioned media of TIMP-3 expressing cells, indicating that 
these proteins can also undergo metalloproteinase-dependent shedding (Fig. 1D, Table 1, Supplemental Table 1), 
potentially by ADAM10. In agreement with this hypothesis, we confirmed by immunoblotting that shedding 
of EphA4 was reduced in the presence of the metalloproteinase inhibitor TAPI and by the ADAM10 specific 
inhibitor GI254023X34,35 (Fig. 2C,D). Nevertheless, we can’t exclude that proteins belonging to this group can 
be shed by another TIMP-3 dependent metalloproteinase or regulated by TIMP-3 through an undefined mech-
anism. All identified peptides of ADAM15 matched with the pro-domain of the enzyme (Fig. 1E) that, simi-
larly to other ADAMs, is cleaved in the Golgi by furin36. This suggests that TIMP-3 can reduce the pro-domain 
removal of ADAM15, and its subsequent secretion in the extracellular environment. The last subgroup of these 
17 membrane proteins with reduced levels comprised 8 further transmembrane proteins, 1 type-1 and 7 type-
2, which are the membrane-bound transcription factor site-1 protease (MBTPS1), mannosyl-oligosaccharide 
1,2-alpha-mannosidase IA (MAN1A1), Alpha-mannosidase 2 (MAN2A1), glycosaminoglycan xylosylkinase 
www.nature.com/scientificreports/
3Scientific RepoRts |  (2018) 8:14697  | DOI:10.1038/s41598-018-32910-4
Figure 1. Secretome analysis of TIMP-3/HEK cells. (A) Number of proteins annotated as membrane or 
secreted proteins out of 1740 proteins in total detected in the secretome of TIMP-3/HEK cells. (B) Topology 
of single-span membrane proteins detected in the secretome of TIMP-3/HEK cells. (C) Volcano plot showing 
the −log10 of p-values versus the log2 of protein ratio between TIMP-3 overexpressing HEK293 cells (T3HEK) 
and control HEK293 cells (ct) of 1740 proteins (n = 6). The horizontal line indicates the –log10(p-value) of 
1.3, which corresponds to a p-value of 0.05. Proteins above this line are considered significantly regulated (red 
dots for upregulated proteins, light blue dots for downregulated proteins). (D) Volcano plot showing the 88 
type-1 (light blue), 46 type-2 (dark blue) and 16 GPI-anchored (grey) transmembrane proteins detected in the 
secretome. Filled dots represent proteins significantly regulated in the secretome of TIMP-3 overexpressing cells 
(p-value below 0.05 – above the horizontal solid line - difference more than 30% - vertical dashed lines), while 
open dots represent proteins not significantly regulated. (E) QARIP analysis of the transmembrane proteins that 
were found significantly reduced in the secretome of TIMP-3-overexpressing cells. QARIP is a webserver that 
matches identified peptides to the protein transmembrane topology19.
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(FAM20B), exostosin-like 2 (EXTL2), exostosin-1 (EXT1), exostosin-2 (EXT2), golgi membrane protein 1 
(GOLM1), mainly located in the endoplasmic reticulum or Golgi apparatus (Fig. 1D, Supplemental Table 1). As 
the QARIP analysis had mapped the identified peptides within the luminal domain of these proteins, it is likely 
that they have undergone metalloproteinase-dependent shedding in the Golgi, where metalloproteases, such as 
ADAM10, can be active37, and that the luminal domains were subsequently released into the extracellular milieu 
(Fig. 1E). Similarly to the ectodomain of transmembrane proteins, a number of ECM proteins, including lamin-
ins, was found less abundant in the conditioned media of TIMP-3-overexpressing cells (Table 1, Supplemental 
Table 1).
Collectively, these data indicate that overexpression of TIMP-3 in HEK293 cells reduces shedding of a diverse 
group of transmembrane proteins, majorly by inhibiting the activity of ADAM10.
Overexpression of TIMP-3 increases levels of LRP-1 ligands. The secretome analysis showed that 
expression of TIMP-3 not only reduced shedding of several membrane proteins, but also induced an increase 
in levels of several soluble proteins, such as the TIMP-3-homolog TIMP-1, macrophage migration inhibitory 
factor 1 (MIF1), osteonectin (SPARC), tissue factor pathway inhibitor (TFPI) and pentraxin-related protein 
(PTX3) (Fig. 1C, Table 1, Supplemental Table 1). Selected proteins – TIMP-1, SPARC and MIF – were further 
analyzed by immunoblots, where the increased levels seen in the mass spectrometric measurement were con-
firmed (Fig. 2E,F). This suggests an involvement of TIMP-3 in the regulation of these proteins. Mechanistically, 
this may occur through their shared binding to LRP-1. TIMP-3 binds LRP-1, and extracellular levels of TIMP-3 
are known to be regulated by LRP-18, an endocytic receptor that binds to and internalizes over fifty proteins via 
four ligand-binding domains (I-IV)10. Different LRP-1 ligands bind to different ligand-binding domains, but also 
to different binding sites within the same ligand-binding domain38,39. Similarly to TIMP-3, TIMP-140 and TFPI41 – 
identified above – are known LRP-1 ligands. Thus, we hypothesized that overexpression of TIMP-3, and its subse-
quent engagement with this endocytic receptor, could increase levels of other ligands that compete with TIMP-3 
for their binding to LRP-1. To test this possibility, we analysed whether similar protein level increases as seen 
with TIMP-3 expression are observed when binding of LRP-1 to its ligands is blocked. To this aim, we used the 
receptor-associated protein (RAP), a known inhibitor of LRP-1, which binds to all four ligand-binding domains 
with the highest affinity among LRP-1 ligands, thus blocking the uptake of all known ligands, and not only of 
TIMP-310. In support of our hypothesis, we found in immunoblots that TIMP-1, MIF and SPARC, which were 
increased in TIMP-3-overexpressing cells, also accumulated in the conditioned media of cells treated with RAP 
(Fig. 3A,B). In addition, to confirm the competition hypothesis, we analysed whether TIMP-3 could compete 
with TIMP-1 for its binding to LRP-1 in vitro. In an ELISA assay, TIMP-1 bound to LRP-1 with a KD,App of 16 nM 
Protein name Gene ID Ratio p-value pept
Selected soluble proteins increased in the conditioned medium of TIMP3 expressing cells
Metalloproteinase inhibitor 3 TIMP3 P35625 793.91 1.65E-05 17
Pentraxin-related protein PTX3 PTX3 P26022 9.55 1.41E-04 18
Metalloproteinase inhibitor 1 TIMP-1 P01033 4.51 1.77E-02 13
Macrophage migration inhibitory factor MIF P14174 2.82 1.02E-02 6
Selected soluble proteins decreased in the conditioned medium of TIMP3 expressing cells
Galectin-3-binding protein LGALS3BP Q08380 0.18 1,99E-02 34
Laminin subunit alpha-4 LAMA4 LAMA4 0.21 2.55E-02 43
Plasma alpha-L-fucosidase FUCA2 Q9BTY2 0.24 4.85E-02 22
Selected membrane proteins showing reduced shedding in TIMP3 expressing cells
Ephrin-B2 EFNB2 P52799 0.22 2.18E-02 5
Protocadherin-9 PCDH9 Q9HC56 0.29 8.61E-03 14
Proprotein convertase subtilisin/kexin type-5 PCSK5 Q92824 0.31 1.37E-02 19
Transforming growth factor beta receptor type 3 TGFBR3 Q03167 0.36 2.73E-02 8
Amyloid-like protein 2 APLP2 Q06481 0.37 1.11E-03 22
Amyloid beta A4 protein APP P05067 0.37 6.66E-03 29
Ephrin type-A receptor 4 EPHA4 P54764 0.44 3.89E-02 7
Neuropilin-1 NRP1 O14786 0.49 4.16E-04 15
Receptor-type tyrosine-protein phosphatase kappa PTPRK Q15262 0.51 2.58E-02 13
Prostaglandin F2 receptor negative regulator PTGFRN Q9P2B2 0.54 6.15E-03 13
Cell adhesion molecule 1 CADM1 Q9BY67 0.65 2.86E-02 8
Anthrax toxin receptor 1 ANTXR1 Q9H6X2 0.71 8.25E-03 3
Neogenin NEO1 Q92859 0.75 5.00E-03 20
Table 1. Changes in protein secretion in TIMP3 expressing cells. ID: Uniprot accession number of the protein. 
Ratio: mean ratio of label-free quantification intensities between HEK/TIMP-3 and control HEK293 cells 
(n = 6). p-value: for six biological replicates. pept: number of identified unique peptides of the protein group.
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Figure 2. Validation of TIMP3/HEK secretome analysis by immunoblotting. (A,B) Immunoblots (A) and 
their respective quantification (B) showing the expression of TIMP-3, sAPP, sAPPα in the conditioned 
media of TIMP3/HEK and control HEK293 cells, and full length APP and actin in cell lysates (densitometric 
quantifications shown as mean values ± standard deviation; *p < 0.05, **p < 0.01, ***p < 0.005, Student’s 
t-test; 3 independent experiments are displayed out of 6 quantified, n = 6). C-D. Immunoblots (C) and their 
respective quantifications (D) showing the decrease of shed EphA4 (sEphA4) in the conditioned media of 
HEK cells cultured in the presence of TAPI or GI254023X (densitometric quantifications shown as mean 
values ± standard deviation; *p < 0.05, **p < 0.01, ***p < 0.005, Student’s t-test; 3 independent experiments 
are displayed out of 6 quantified, n = 6). (E,F) Immunoblots (C) and their respective quantification (D) showing 
the increase of TIMP-1, MIF and SPARC in the conditioned media of TIMP-3 expressing cells (densitometric 
quantifications shown as mean values ± standard deviation; *p < 0.05, **p < 0.01, ***p < 0.005, Student’s t-test; 
3 independent experiments are displayed out of 6 quantified, n = 6). MMP-1 is shown as an example of a protein 
that does not increase in the conditioned media of TIMP-3/HEK293.
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(Fig. 4A), in agreement with previous reports40. The addition of 2 nM TIMP-3 (a concentration similar to that of 
its binding KD for the receptor38) was sufficient to reduce the amount of TIMP-1 that binds to LRP-1 by about 40% 
(Fig. 4B). Levels of TIMP-2, another known LRP-1 ligand42, accumulated as expected in the conditioned media 
in the presence of RAP (Fig. 3A,B), but were not increased in TIMP-3/HEK (Fig. 1C). This suggests that TIMP-2 
may bind to a separate site from that of TIMP-3, so that RAP, but not TIMP-3-overexpression affects its turnover 
and therefore its extracellular levels.
Besides the LRP-1 ligands TIMP-1, MIF, SPARC and TFPI, additional soluble proteins were upregulated in 
TIMP-3 expressing cells (Fig. 1C). To determine which of them may be additional potential LRP-1 ligands, we 
analysed the conditioned media of RAP-treated HEK293 cells by using a similar proteomic approach as in Fig. 1 
and compared the results with the secretome of TIMP-3/HEK cells. The secretome analysis of RAP-treated cells 
identified 412 proteins annotated as membrane proteins and 258 proteins annotated as secreted ones (Fig. 5A,B). 
Together with RAP (identified by the gene name LRPAP1 in the volcano plot), levels of 34 secreted proteins 
were significantly (i.e. proteins whose levels changed by at least 30% with a p-value of their change below 0.05) 
increased in the presence of RAP (Fig. 5B). As expected, TIMP-1, MIF and TFPI, which were increased in the 
secretome of TIMP-3-overexpressing cells, were also found increased in the secretome of RAP-treated cells. MIF 
and TFPI were only found in the secretome of RAP-treated but not control cells and are therefore not shown in 
the volcano plot in Fig. 5C, (see also Supplemental Table 1). Similarly, IGFBP4 and CHGA were only found in 
the secretome of TIMP-3/HEK and RAP-treated HEK cells, but not in their respective controls. Additionally, 
PSAP was upregulated in the secretome of both TIMP-3/HEK and RAP-treated cells (Fig. 5C), suggesting that 
all three proteins were upregulated in the TIMP-3/HEK secretome and that this is because they are new LRP-1 
ligands. In addition, RAP treatment increased levels of a higher number of secreted proteins compared to TIMP-
3-overexpression, presumably because they have binding sites in LRP-1 that are different from the TIMP-3 
binding site. Among these, many are already established LRP-1 ligands, including TIMP-242, the tissue-type 
plasminogen activator (PLAT)43 and midkine (MDK)44 (Fig. 5B,C, Table 2). Other secreted proteins which 
were upregulated in the presence of RAP, including the insulin-like growth factor-binding protein 2 (IGFBP-2), 
ADAMTS-1 and the glia-derived nexin (SERPINE2), have high probability to be novel LRP-1 ligands, as they 
belong to families of proteins that are known to interact with the receptor. Indeed, other members of the IGFBP 
family of proteins45, several serpins46 and the other two aggrecanases ADAMTS-4 and -547,48 have been identified 
as LRP-1 ligands. Conversely, only 6 secreted proteins and the ectodomains of 2 transmembrane proteins (DSG1 
and PCDH7) were reduced upon RAP treatment, while the majority of shed ectodomains were not altered, indi-
cating that RAP had no major effects on protein shedding (Fig. 5B and Supplemental Table 1). In agreement, 
immunoblotting confirmed that RAP did not alter the shedding of APP and EphA4 (Fig. 5D–G).
Figure 3. RAP increases levels of specific proteins. (A,B) Immunoblots and their respective quantification 
showing levels of specific proteins (TIMP-3, TIMP-1, TIMP-2, SPARC, MIF) in the conditioned media 
of HEK293 cells in the presence or absence of RAP (densitometric quantifications shown as mean 
values ± standard deviation; *p < 0.05, **p < 0.01, ***p < 0.005, Student’s t-test; 3 independent experiments are 
displayed out of 6–8 quantified, n = 6–8).
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In conclusion, our study suggests that levels of a number of secreted proteins, including TIMP-1, are increased 
in TIMP-3-overexpressing cells as a consequence of their competition with TIMP-3 for the binding to LRP-1. In 
addition to them, we identified several proteins accumulating in the conditioned media upon LRP-1 inactivation, 
that are likely to be novel LRP-1 ligands.
Discussion
TIMP-3 is an endogenous inhibitor of metalloproteinases, and as such, an essential regulator of ECM turnover1. 
TIMP-3 has proved beneficial in diseases characterized by enhanced proteolysis, including arthritis and can-
cer13,15; thus, approaches to increase its bioavailability in the tissue have been developed for the therapy of such 
diseases16,38,49. However, given that TIMP-3 has numerous targets and binding partners, a therapeutic increase 
of TIMP-3 levels may lead to mechanism-based side effects. In order to predict molecular pathways that can be 
affected by high doses of TIMP-3, we took advantage of a quantitative, high-resolution mass spectrometric work-
flow to investigate changes in the cell secretome upon overexpression of the inhibitor. By using this method, we 
identified two major classes of proteins whose release is altered in the presence of high TIMP-3 levels: transmem-
brane proteins that undergo metalloproteinase-mediated shedding, in particular ADAM10 substrates, and LRP-1 
ligands that may compete with TIMP-3 for the binding to the receptor.
First, we found that the ectodomain of several transmembrane type-1 proteins detected in the conditioned 
media were decreased in the presence of TIMP-3, suggesting inhibition of their ectodomain shedding. A large 
fraction of these proteins are established substrates of ADAM10, including APP37,50. In addition, TIMP-3 overex-
pression led to a decrease of different transmembrane protein ectodomains whose sheddase has not been identi-
fied yet, including protocadherin-9, ephrin type-A receptor 4, prostaglandin F2 receptor negative regulator and 
anthrax toxin receptor 1, indicating them as novel substrates of a metalloproteinase, potentially of ADAM10. 
In addition to being the physiological α-secretase of the Alzheimer APP protein22, ADAM10 controls several 
biological processes by shedding various substrates37,50. Its ablation in mouse is embryonically lethal, as a result 
Figure 4. TIMP-3 competes with TIMP-1 for its binding to LRP-1. (A) Full-length LRP1 was coated onto 
microtiter plates and binding of FLAG-tagged TIMP-1 (0–48 nM) was measured using an M2 anti-FLAG 
antibody (n = 3). (B) Similarly, binding of 24 nM FLAG-tagged TIMP-1 to LRP-1 was measured in the absence 
(control) or presence of 2 nM TIMP-3.
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Figure 5. Secretome analysis of RAP-treated HEK293 cells. (A) Topology of all the proteins detected in the 
secretome of RAP-treated HEK293 cells. (B) Volcano plot showing the −log10 of p-values versus the log2 of 
protein ratio between HEK293 cells in the presence and absence of RAP (left). RAP itself was also identified and 
is shown in the plot under the gene name ‘LRPAP1’. From this analysis, a volcano plot showing only secreted 
proteins was extracted (right). The horizontal solid line indicates the –log10(p-value) of 1.3 (corresponding 
to a p-value of 0.05). Proteins above this line are considered significantly regulated (red dots for upregulated 
proteins, light blue dots for downregulated proteins, (n = 6). (C) Venn diagram showing secreted proteins that 
are upregulated in either TIMP-3/HEK or RAP-treated HEK293 secretomes (p-values < 0.05, and proteins 
found only in TIMP-3/HEK or RAP-treated secretomes, but not in the control). In the intersection between 
the two diagrams are listed proteins upregulated in both secretomes. (D–G) Immunoblots (D,F) and their 
respective quantifications (E–G) showing that addition of 500 nM RAP to HEK293 cells does not alter shedding 
of APP (D,E) and EphA4 (F,G, displayed bands were run on the same blot but not directly next to each other) 
(densitometric quantifications shown as mean values ± standard deviation; *p < 0.05, **p < 0.01, ***p < 0.005, 
Student’s t-test; 2 independent experiments are displayed out of 6 quantified, n = 6).
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of the loss of cleavage and signaling of the Notch receptor, a well-characterized ADAM10 substrate51. Thus, we 
speculate that sustained TIMP-3 expression, and the consequent persistent inhibition of ADAM10, as well as 
the inhibition of other metalloproteinases, can have detrimental effects in vivo. In support of this hypothesis, 
transgenic mice overexpressing TIMP-3 in chondrocytes display abnormalities in bone development, including 
decreased osteoblast differentiation and reduction in growth plate length and bone mass52,53. Such a phenotype 
may be due to dysregulation of Notch signaling, which plays a crucial role in maintaining bone homeostasis by 
regulating proliferation and differentiation of both osteoblasts and osteoclasts54. Furthermore, we found that 
overexpression of TIMP-3 led to a decrease in abundance of a number of soluble proteins in the secretome, 
including galectin-3-binding protein, plasma alpha-L-fucosidase and several laminin subunits. Laminins are het-
erotrimeric proteins (containing an alpha, a beta and a gamma-chain) that connect cells to the ECM by binding 
cell surface receptors, such as integrins, and ECM components55. Several laminin subunits, including laminin 
alpha-4, alpha-1, alpha-5, beta-1 and gamma-1 were decreased in the conditioned media in the presence of high 
levels of TIMP-3. This indicates that overexpression of TIMP-3 may stabilize laminin receptors on the cell surface, 
thereby decreasing soluble levels of these proteins in the extracellular milieu.
Second, overexpression of TIMP-3 promoted accumulation of a number of secreted proteins that are known 
to be LRP-1 ligands, including TIMP-1, another member of the TIMP family40. We hypothesized that the accu-
mulation of TIMP-1 in the conditioned media of TIMP-3-overexpressing cells can be due to its competition with 
TIMP-3 for binding to the LRP-1 receptor. Thus, TIMP-3-overexpression may trigger a positive feedback loop 
that enhances the bioavailability of both TIMP-1 and TIMP-3. Similarly to TIMP-3, TIMP-1 is able to inhibit 
ADAM1056, thus, increased levels of both TIMPs upon TIMP-3 overexpression may function additively to inhibit 
MMP-mediated ECM proteolysis and the activity of ADAM10. In contrast to TIMP-3 that binds to LRP-1 within 
the N-terminal half of the ligand binding domain II38, RAP interacts with all four ligand binding domains, thus 
inhibiting the uptake of all known ligands of LRP-1. In agreement, RAP increased levels of a higher number of 
proteins in the secretome than was seen with TIMP-3 overexpression. Among these, RAP increased levels of 
proteinases, including ADAMTS-1 and PLAT, and proteinase inhibitors, such as TIMPs. Previous studies showed 
that, despite increasing both proteinases and proteinase inhibitors, the overall effect of LRP-1 inactivation on 
ECM turnover is promoting its catabolism. Indeed, LRP-1 inactivation by RAP induces aggrecan degradation in 
explants of porcine articular cartilage48, and its genetic ablation in fibroblasts increases turnover of fibronectin 
and collagen57. We found that levels of the tissue-type plasminogen activator (PLAT) were more than 25-fold 
higher in the presence of RAP compared to controls. PLAT is a serine protease that cleaves plasminogen into 
active plasmin, which in turn promotes ECM degradation58,59. In addition to plasminogen, PLAT can activate 
the urokinase-type plasminogen activator and several MMPs, including MMP-960–62. It is interesting to speculate 
that such high levels of PLAT accumulating in the conditioned medium as a consequence of LRP-1 inactivation 
can trigger a proteinase activation cascade that would exceed the inhibitory potential of TIMPs and serpins, thus 
promoting ECM breakdown. In agreement, we found that RAP increased levels of a number of ECM proteins in 
the secretome, including nidogens, laminins, collagens and fibronectin, in addition to LRP-1 ligands. The increase 
of these ECM proteins may be due to enhanced ECM catabolism, which renders fragments of these proteins more 
available in the extracellular milieu.
Protein name Gene ID Ratio p-value pept
Alpha-2-macroglobulin receptor-associated protein LRPAP1 P30533 229.36 1.67E-03 63
Insulin-like growth factor-binding protein 2 IGFBP2 P18065 65,40 2.71E-06 16
Fibrillin-2 FBN2 P35556 36.40 5.07E-06 50
SPARC-related modular calcium-binding protein 1 SMOC1 Q9H4F8 31.97 6.43E-05 18
Tissue-type plasminogen activator PLAT P00750 25.58 7.18–03 21
Carboxypeptidase E CPE P16870 24.61 8.57E-05 19
Fibronectin FN1 P02751 6,81 8.23E-04 63
Nidogen-2 NID2 Q14112 4.60 1.64E-03 53
Metalloproteinase inhibitor 2 TIMP2 P16035 6.46 4.50E-03 10
Laminin subunit beta-1 LAMB1 P07942 4.89 4.91E-03 60
Collagen alpha-1 COL2A1 P02458 4.77 1.83E-03 10
A disintegrin and metalloproteinase with thrombospondin motifs 1 ADAMTS1 Q9UHI8 4.62 8.25E-05 28
Nidogen-1 NID1 P14543 4.60 1.64E-03 56
Laminin subunit alpha-4 LAMA4 Q16363 4.60 1.09E-03 39
Phospholipid transfer protein PLTP P55058 4.59 3.21E-02 11
Metalloproteinase inhibitor 1 TIMP1 P01033 4.30 7.29E-03 8
Fibulin-1 FBLN1 P23142 4.12 2.18E-02 29
Glia-derived nexin SERPINE2 P07093 4.02 2.98E-02 13
Table 2. SECRETED proteins increased in the conditioned medium of RAP-TREATED HEK293 cells. ID: 
Uniprot accession number of the protein. Ratio: mean ratio of label-free quantification intensities between 
RAP-treated and control HEK293 cells (n = 6). p-value: for six biological replicates. pept: number of identified 
peptides of the protein group.
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In conclusion, TIMP-3 is considered a valuable target for the therapy of conditions associated with enhanced 
proteolysis, including arthritis and cancer. Different therapeutical approaches have been developed to increase the 
bioavailability of TIMP-3 in the tissue, including injections of recombinant TIMP-3 or adenovirus-mediated gene 
delivery15,16. Our data suggest that such approaches may affect dramatically cell behaviour, by inhibiting shedding 
of several proteins at the cell surface, in addition to influencing the turnover of ECM proteins. This must be taken 
into a consideration when developing therapies based on TIMP-3, as too high levels of the inhibitor can have 
harmful consequences on tissue homeostasis.
Methods
Secretome analysis of TIMP-3-expressing cells. TIMP-3 stably-transfected HEK293 cells (TIMP-3/
HEK) were generated as previously described18, and maintained in DMEM with 10% FCS, 100 U/ml penicillin 
and 100 U/ml streptomycin, 800 μg/mL hygromycin B at 37 °C in 5% CO2. TIMP-3/HEK or HEK293 cells were 
cultured in 10 cm dishes until confluence and then incubated in serum-free DMEM. After 48 h, supernatants were 
harvested and centrifuged to remove cell debris. Protein concentration in supernatants was measured using the 
colorimetric 660 nm assay (Thermo Fisher Scientific, US). A protein amount of 30 μg per sample was subjected 
to proteolytic digestion using the filter assisted sample preparation (FASP) protocol with 10 kDa Vivacon spin 
filters (Sartorius, Germany)63. Proteins were digested with 0.5 μg LysC (Promega) over-night and subsequently 
with 0.5 μg trypsin (Promega) for 4 h at 37 °C. Peptides were desalted by stop-and-go extraction (STAGE) on 
reverse phase C1864, and eluted using 40 μl of 60% acetonitrile in 0.1% formic acid. The volume was reduced 
in a SpeedVac and the peptides were resuspended in 0.1% formic acid for LC-MS/MS analysis. To achieve high 
sensitivity, a nanoLC-MS/MS setup was used that included a nanoLC system (EASY-nLC 1000, Proxeon – part 
of Thermo Scientific, US) with an in-house packed C18 column (30 cm × 75 μm ID, ReproSil-Pur 120 C18-AQ, 
1.9 μm, Dr. Maisch GmbH, Germany) coupled online via a nanospray flex ion source equipped with a PRSO-V1 
column oven (Sonation, Germany) to a Q-Exactive mass spectrometer (Thermo Scientific, US). 1 μg of peptides 
were separated using a binary gradient of water and acetonitrile containing 0.1% formic acid at 50 °C column 
temperature, using the settings for this system shown in Table 3.
Proteomic data analysis. The data was analyzed by the software Maxquant (maxquant.org, Max-Planck 
Institute Munich) version 1.5.2.6. The MS data was searched against a reviewed canonical fasta database of Homo 
sapiens from UniProt (download: December 12th 2014, 16685 entries). Trypsin was defined as protease. Two 
missed cleavages were allowed for the database search. The option first search was used to recalibrate the peptide 
masses within a window of 20 ppm. For the main search peptide and peptide fragment mass tolerances were set to 
4.5 and 20 ppm, respectively. Carbamidomethylation of cysteine was defined as a static modification. Acetylation 
of the protein N-terminus as well as oxidation of methionine set as variable modifications. Label free quantifi-
cation (LFQ) of proteins required at least two ratio counts of unique peptides. Only unique peptides were used 
for quantification. The LFQ values were log2 transformed and a two-sided Student’s t-test was used to evaluate 
proteins statistically significantly regulated between TIMP-3-overexpressing HEK293 and control cells. A p-value 
less than 0.05 was set as the significance threshold.
Validation of regulated proteins by immunoblotting. A number of selected proteins that were 
detected as regulated in the analysis were further validated by immunoblotting (TIMP-3, TIMP-1, SPARC, MIF, 
APP). Supernatants from TIMP-3/HEK or HEK293 cells were loaded onto an acrylamide gel for electrophoresis. 
After electrophoretic separation, proteins were blotted onto a PVDF membrane using the Trans-Blot Turbo trans-
fer system (Biorad) and detected by the following antibodies: anti-TIMP-3 (AB6000, Millipore), anti-TIMP-1 
(generated as previously described65), anti-TIMP-2 (generated as previously described66), anti-SPARC (number 
5031, Thermo Fisher), anti-MIF (clone FL-115, Santa Cruz) anti-APP (clone 22C11, Millipore), anti-MMP-1 
(clone 2A7.2, Millipore) anti-actin (A5316, Sigma Aldrich).
Bands corresponding to each protein were quantified by using Multi Gauge software (Fujifilm) and normal-
ized to the mean of the original non-normalized control values (HEK293 cells). A two-sided Student’s t-test 
was used to evaluate proteins statistically significantly regulated, with a p-value less than 0.05 that was set as the 
significance threshold.
Validation of EphA4 as an ADAM10 substrate. HEK293 cells were treated with TAPI (Sigma-Aldrich 
SML0739, final concentration: 50 μM), GI254023X (Sigma-Aldrich, SML0789, final concentration: 5 μM) 
or DMSO for 24 h in serum-free DMEM. Then, conditioned media were collected and concentrated by 
Time [min] Duration [min] Flow [nL/min] acetonitrile [%]
0 — 50 2
5 5 250 5
185 180 250 25
230 45 250 35
250 20 250 60
255 5 250 95
Table 3. LC gradient for the separation of tryptic peptides for LC-MS/MS analysis.
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TCA-precipitation. Cells were collected with STET lysis buffer (50 mM Tris, pH 7,5, 150 mM NaCl, 2 mM EDTA, 
1% Triton), containing protease inhibitor cocktail (1:500, Sigma, P-8340). Conditioned media and cell lysates were 
loaded onto an acrylamide gel for electrophoresis and blotted onto a PVDF membrane. Proteins were detected 
with an anti-EphA4 antibody (number 610471, BD Biosciences) and anti-calnexin (number ADI-SPA-860, Enzo 
Life Sciences, Germany).
ELISA to analyse binding of TIMP-1 to LRP-1. Recombinant human C-terminally FLAG-tagged 
TIMP-1 was generated with a modification of the method previously described for purifying TIMP-318. Briefly, 
TIMP-1 was expressed using a pCEP4-based expression vector (Invitrogen, UK) constructed by the PCR method. 
Human embryonic kidney HEK293 cells were transfected with the expression plasmid by using Lipofectamine 
2000 (Thermo Fisher Scientific). 48 h after transfection, cells were incubated in serum-free DMEM for 4 days. 
Then, conditioned medium was collected, centrifuged to remove cell debris and applied to a column of anti-FLAG 
M2-agarose (0.5 ml, Sigma-Aldrich). The column was washed with TNC, and bound protein eluted with 200 μg/
ml FLAG peptide (Sigma-Aldrich, UK) in TNC buffer. To remove the FLAG peptide, the eluate was applied to 
a Vivaspin column with a 10 kDa membrane cut-off (Sartorius, Germany). The identity of the protein was con-
firmed by immunoblotting, and its active concentration was measured by titration against a known concentration 
of MMP-1 catalytic domain.
2 nM human LRP1 (Biomac, Germany) in TNC (50 mM Tris/HCl, 150 mM NaCl, 10 mM CaCl2, pH 7.4) was 
coated overnight at 4 °C onto microtiter plates. Wells were blocked with 3% BSA in TNC (1 h; 37 °C) and washed 
in TNC containing 0.05% (v/v) Brij-35 after this and each subsequent step. Wells were then incubated with var-
ious concentrations of FLAG-tagged TIMP-1 (0–48 nM) either alone or in the presence of 2 nM TIMP-3 (R&D 
Systems) in blocking solution for 3 h at room temperature. Bound TIMP-1 was detected using anti-FLAG M2 
mouse monoclonal antibody (Sigma-Aldrich) and then with an anti-mouse secondary antibody coupled to horse-
radish peroxidase (Promega). Hydrolysis of tetramethylbenzidine substrate (slow kinetic form, Sigma-Aldrich) 
was measured at 450 nm using a Tecan infinite m200 pro absorbance microplate reader (Tecan, Switzerland). 
Results were analysed by Graphpad Prism software, which was used to generate the binding curve (using the 
one-site saturation binding function) and extrapolate the KD,App.
Secretome analysis of RAP-treated HEK293 cells. The receptor-associated protein RAP was puri-
fied as previously described48. Briefly, recombinant human His-tagged RAP was expressed in Escherichia coli 
BL21(DE3) using a pET3a-based expression vector (Novagen/EMD Biosciences), and purified from the soluble 
fraction of the cell lysate by using a nickel-nitrilotriacetic acid Superflow resin (Qiagen). After washing the col-
umn with 20 mM HEPES (pH 7.5), 1 M NaCl, and 50 mM imidazole, bound protein was eluted in 20 mM HEPES 
(pH 7.5), 150 M NaCl, and 500 mM imidazole. HEK293 cells were cultured in 6-well plates until confluence 
and then incubated in serum-free DMEM with or with out 500 nM RAP for 24 h. Supernatants were harvested 
and analysed by LC-MS/MS using the same method used to analyse supernatants of TIMP-3/HEK cells. Briefly, 
supernatants were harvested and centrifuged to remove cell debris, prior to being concentrated in 10 kDa Vivacon 
spin filters and subjected to FASP. Proteolytic peptides were desalted using STAGE tips. The purified peptides 
were dried by vacuum centrifugation and resuspended in 10 μL 0.1% formic acid and analyzed by LC-MS/MS.
Some of the proteins that were significantly regulated in the conditioned media of RAP-treated HEK293 cells 
(TIMP-3, TIMP-1, TIMP-2, MIF and SPARC, primary antibodies described above), together with proteins whose 
shedding was not affected by RAP (APP and EphA4), were further validated by Western blotting. Cells were 
grown to confluence in 6-well plates, and then incubated for 24 h in serum-free DMEM, with or without RAP. 
After collection, supernatants were concentrated by TCA-precipitation and loaded onto an acrylamide gel for 
electrophoresis and Western blotting. Bands corresponding to each protein were quantified and analysed for their 
statistically significant regulation as described above. All test were done on an exploratory 2-sided 5% significance 
level.
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